Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Vir Biotechnology Surges on Evidence Therapy Useful Against Omicron

Published 15/12/2021, 16:20
Updated 15/12/2021, 16:20
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – Vir Biotechnology stock (NASDAQ:VIR) climbed 14% Wednesday after the company said it has more data showing that its Covid-19 antibody therapy is effective against the Omicron variant.

Labelled "of concern" by the World Health Organization, Omicron has been reported in more than 60 countries, including China, and now dominates the Delta variant in many nations. Said to be spreading faster than Delta, Omicron has forced countries in Europe and Australia to bring back restrictions on the movement of people and business activities.  

The company said sotrovimab, the investigational SARS-CoV-2 neutralizing monoclonal antibody it developed with GlaxoSmithKline (NYSE:GSK), has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by the virus and to have an extended half-life. ADRs of GSK traded 0.3% higher. 

According to Vir, there are five more preclinical monoclonal antibodies, also developed with GSK, which retained their in vitro neutralizing activity against Omicron.

The findings have yet to be published in a peer-reviewed medical journal.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.